It has been 12 years since the publication of the National Kidney Foundation–Kidney Disease Outcomes Quality Initiative (NKF-KDOQI) guideline for evaluation, classification, and stratification of chronic kidney disease (CKD).1 While not a new medication, a new device, or a landmark clinical trial, this guideline publication perhaps had a greater impact on the diagnosis and management of people with CKD than anything else that has happened in nephrology in the first decade of the 21st century.
CommentaryKDOQI US Commentary on the 2012 KDIGO Clinical Practice Guideline for the Evaluation and Management of CKD
Section snippets
Foreword
Review and Approval Process for this Commentary
To assist US practitioners in interpreting the KDIGO guideline, the NKF-KDOQI convened a work group to write a commentary. The commentary addresses the full scope of the KDIGO guideline, focusing in particular on their relevance to and implementation in the United States. The NKF-KDOQI Steering Committee first selected Co-Chairs and then individual members based on their clinical and/or research expertise and interest in the guideline process. Individual sections focusing on each of the topic
Definition of CKD
CKD is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health. (Not Graded) [See table titled “Criteria for CKD (either of the following present for >3 months)”] Abbreviations: CKD, chronic kidney disease; GFR, glomerular filtration rate.
Definition and Identification of CKD Progression
Assess GFR and albuminuria at least annually in people with CKD. Assess GFR and albuminuria more often for individuals at higher risk of progression, and/or where measurement will impact therapeutic decisions. (Not Graded) Recognize that small fluctuations in GFR are common and are not necessarily indicative of progression. (Not Graded) Define CKD progression based on one of more of the following (Not Graded): Decline in GFR category (≥90 [G1], 60–89 [G2], 45–59 [G3a], 30–44 [G3b], 15–29 [G4], <15
Prevention of CKD Progression (Recommendations 3.1.1-3.1.11)
BP and RAAS interruption Individualize BP targets and agents according to age, coexistent cardiovascular disease and other comorbidities, risk of progression of CKD, presence or absence of retinopathy (in CKD patients with diabetes), and tolerance of treatment as described in the KDIGO 2012 Blood Pressure Guideline. (Not Graded) Inquire about postural dizziness and check for postural hypotension regularly when treating CKD patients with BP-lowering drugs. (Not Graded) Tailor BP treatment regimens
CKD and CVD
We recommend that all people with CKD be considered at increased risk for cardiovascular disease. (1A) We recommend that the level of care for ischemic heart disease offered to people with CKD should not be prejudiced by their CKD. (1A) We suggest that adults with CKD at risk for atherosclerotic events be offered treatment with antiplatelet agents unless there is an increased bleeding risk that needs to be balanced against the possible cardiovascular benefits. (2B) We suggest that the level of
Referral to Specialist Services
We recommend referral to specialist kidney care services for people with CKD in the following circumstances (1B): AKI or abrupt sustained fall in GFR; GFR < 30 ml/min/1.73 m2 (GFR categories G4-G5)∗; a consistent finding of significant albuminuria (ACR ≥ 300 mg/g [≥ 30 mg/mmol] or AER ≥ 300 mg/24 hours, approximately equivalent to PCR ≥ 500 mg/g [≥50 mg/mmol] or PER ≥ 500 mg/24 hours); progression of CKD (see Recommendation 2.1.3 for definition); urinary red cell casts, RBC >20 per high power field sustained and not
Conclusion
The KDIGO guideline recommendations on evaluation and management of CKD serve as an excellent summary of the state our knowledge and available evidence on CKD. Importantly, they provide an important and needed update to the staging system based on newly available data. They also highlight gaps in knowledge to guide future investigative efforts.
Acknowledgements
Guideline recommendations included in this article originally were published in Kidney International Supplements and were reproduced with permission from KDIGO.
We thank Drs Jeffrey Berns, Michael Choi, Holly Kramer, Michael Rocco, and Joseph Vassalotti for careful review of this manuscript; and Kerry Willis, Emily Howell, and James Papanikolaw from the NKF for help in coordinating the work of the group and preparing the manuscript.
Support: No financial support was required for the development
References (83)
A decade after the KDOQI CKD guidelines
Am J Kidney Dis
(2012)- et al.
Evidence and outcomes in CKD
Am J Kidney Dis
(2012) - et al.
The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report
Kidney Int
(2011) - et al.
Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts
Kidney Int
(2011) - et al.
Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts
Kidney Int
(2011) - et al.
Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes in both general and high-risk populations. A collaborative meta-analysis of general and high-risk population cohorts
Kidney Int
(2011) - et al.
GFR prediction from cystatin C and creatinine in children: effect of including body cell mass
Am J Kidney Dis
(2012) - et al.
Estimating kidney function in a multiethnic Asian population with multiple filtration markers
Am J Kidney Dis
(2012) - et al.
Paradoxical association between body mass index and mortality in men with CKD not yet on dialysis
Am J Kidney Dis
(2007) - et al.
Prospective nutritional surveillance using bioelectrical impedance in chronic kidney disease patients
J Ren Nutr
(2005)
The Framingham predictive instrument in chronic kidney disease
J Am Coll Cardiol
C-Reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease
Kidney Int
Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial
J Am Coll Cardiol
The efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or moderate chronic kidney disease: results from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial
Am Heart J
Renin angiotensin system blockade and cardiovascular outcomes in patients with chronic kidney disease and proteinuria: a meta-analysis
Am Heart J
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial
Lancet
Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials
J Card Fail
Association of N-terminal pro-B-type natriuretic peptide with left ventricular structure and function in chronic kidney disease (from the Chronic Renal Insufficiency Cohort [CRIC])
Am J Cardiol
Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF
Am J Kidney Dis
Cardiac troponin I concentration is commonly increased in nondialysis patients with CKD: experience with a sensitive assay
Am J Kidney Dis
The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age
Kidney Int
Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort
Am J Kidney Dis
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized placebo-controlled trial
Lancet
K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification
Am J Kidney Dis
KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease
Kidney Int Suppl
Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis
Lancet
Screening for chronic kidney disease: U.S. Preventive Services Task Force recommendation statement
Ann Intern Med
Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
Hypertension
Standards of medical care in diabetes—2013
Diabetes Care
A new equation to estimate glomerular filtration rate
Ann Intern Med
Estimating glomerular filtration rate from serum creatinine and cystatin C
N Engl J Med
Two novel equations to estimate kidney function in persons aged 70 years or older
Ann Intern Med
Cystatin C versus creatinine in determining risk based on kidney function
N Engl J Med
A reference system for urinary albumin: current status
Clin Chem Lab Med
Overview of the Alberta Kidney Disease Network
BMC Nephrol
One-year change in kidney function is associated with an increased mortality risk
Am J Nephrol
Short-term change in kidney function and risk of end-stage renal disease
Nephrol Dial Transplant
KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease
Kidney Int Suppl
KDOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease
Am J Kidney Dis
Cited by (1227)
Framework of Guidelines for Management of CKD in Asia
2024, Kidney International Reports